Crafting life changing therapies
Crafting life changing therapies
At Quell we see a future where serious immune-mediated and inflammatory disease can be durably controlled with a single dose of engineered Tregs.
Our Mission
We discover, develop, and deliver pioneering Treg therapies to durably transform the lives of people suffering from immune-mediated diseases.
Anchored by Values, Propelled by Purpose
People
A visionary team, passionately committed to delivering Quell's mission
Quell’s seasoned leadership team is dedicated to the delivery of transformative therapies to patients. Their extensive experience across all aspects of cell therapy development ensures continued leadership and innovation in the engineered Treg field.
Annette Clancy
Non-Executive Director
Annette has over 35 years’ experience in the Pharmaceutical/Biopharmaceutical Industry, working across a variety of functions (R&D, Commercial, Worldwide Business Development) in the US and UK. Her Pharmaceutical career spanned 15 years at GSK, with an Executive role leading the global Transactions and Alliance Business Development team where she was led multibillion - dollar deals/M&A.
Since Annette’s retirement from GSK in December 2008, she has worked with US and European Venture Capital/Private Equity groups and served as Chair of the Board, or, as Non -Executive Board member, for various public and private US and European Biotechnology companies. Most recently she Chaired SOBI, a leading public company in rare diseases. She is currently an Operational Investor for Jeito Capital.
Our Partners
Partnering is in our DNA
We recognise that winning in a pioneering field means collaborating with the smartest people, to gain the best insights. At Quell, we look to partner with the leaders in their field, who share the common goal of accelerating life changing therapies to patients.
Biopharma
In the spirit of ‘partnering with the best’, Quell are always looking for world-leading pharma partners to collaborate with, sharing a clear goal of bringing together complimentary skill sets and knowledge bases, which together help us move the field forward, develop better therapeutics and change patients lives.
Quell’s recent collaboration with AstraZeneca is the perfect example of this - joining together on the journey to develop best-in-class therapies for type 1 diabetes and inflammatory bowel disease.
Academic
We understand that partnering with academia can help us unlock biologic insights, and optimise a highly translational product development cycle. If your lab is exploring the biology of Tregs which might unlock therapeutic approaches, we’d be keen to hear from you.
We collaborate with Kings College London, University College London, University Health Network, Hannover Medical School, University of Florida, University of Pittsburgh and many more.
Manufacturing
We can claim with real conviction that Quell understands Treg manufacturing better than any other organisation or institution on the planet. We got to this stage through collaboration with leading technology platforms, and academic / industrial partners. Together we are unlocking the platform for commercial scale Treg therapeutics.
Investors
Our Partners
At Quell we are passionate about our mission for bringing lifechanging immune-therapies of the future, into our world of today – We are pleased to be partnered with investors who collectively share our passion and our values.
